Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals is a U.S.-based commercial-stage biopharmaceutical company focused on targeted therapies for childhood and adult cancers. Its current business centers on OJEMDA for relapsed or refractory pediatric low-grade glioma and on advancing a pipeline that includes DAY301 and other oncology programs through in-licensing, clinical development, and selective partnerships.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueOJEMDA is the company’s approved product for relapsed or refractory pLGG in the U.S.
Includes DAY301, the VRK1 inhibitor program, and other development assets.
License and service revenue from partnering rights outside the U.S. and related R&D services.
Products
Reported · share of revenue- Products98.3 %
- License1.7 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Day One sells primarily into a narrow specialist oncology channel in the United States, where pLGG is treated by a focused group of pediatric and neuro-oncology specialists. Its access and distribution model also depends on managed care, government payers, hospital systems, specialty distributors, and specialty pharmacies to secure coverage and patient access. Outside the U.S., the company relies on Ipsen to commercialize OJEMDA, so the end customer base is reached through a partner rather than Day One’s own sales force.
Pediatric and neuro-oncology specialists prescribe OJEMDA for relapsed/refractory pLGG and drive adoption.
Managed care, government payers, and hospital systems influence coverage, reimbursement, and patient access.
Specialty pharmacies and distributors dispense OJEMDA and support the narrow rare-disease channel.
Ipsen commercializes OJEMDA outside the U.S. under the license agreement.
Investigators and trial sites enroll patients for DAY301 and other pipeline programs.
Strategy
The company is transitioning from a development-focused biotech into a commercial oncology business built around OJEMDA while expanding its pipeline. Its strategy is to source differentiated assets through business development, move them through clinical development, and use partnerships where they improve speed or market reach. Day One also aims to keep a lean U.S. commercial footprint by focusing on a concentrated specialist channel and outsourcing ex-U.S. commercialization to Ipsen.
The company’s near-term revenue base depends on penetration of the small specialist pLGG market and payer access.
Pipeline progression is needed to diversify the company beyond a single commercial asset.
In-licensing can expand the pipeline faster than internal discovery alone.
Partnering reduces the need to build international commercial infrastructure and can accelerate market entry.
Geography
Day One is headquartered in Brisbane, California and generates product revenue primarily in the United States from OJEMDA. Internationally, the company has licensed ex-U.S. commercialization rights for OJEMDA to Ipsen, which shifts non-U.S. market execution and some regulatory/commercial risk to a partner. Its pipeline also depends on global third-party manufacturers and collaborators, including MabCare in Shanghai, China.
Risks
Day One faces the typical risks of a commercial-stage biotech with a short operating history: dependence on a single approved product, uncertain clinical outcomes for pipeline assets, and heavy reliance on third parties for manufacturing and trial execution. Commercial success also depends on payer coverage, regulatory approvals, patent protection, and the company’s ability to scale operations without losing focus or talent.
- Dependence on OJEMDA as the only commercial productImpact: HighLikelihood: Medium
A single-product revenue base makes the business sensitive to launch execution, payer access, and competitive or regulatory setbacks.
Exposure: U.S. commercial revenue
- Clinical development failure for DAY301 and other pipeline assetsImpact: HighLikelihood: Medium
The company’s growth strategy relies on successful trial results and regulatory approval for new programs.
Exposure: Pipeline value creation
- Third-party manufacturing and supply chain disruptionImpact: HighLikelihood: Medium
The company depends on external manufacturers for product and candidate supply, which can delay trials or commercial shipments.
Exposure: Clinical and commercial supply
- Patent and exclusivity erosionImpact: HighLikelihood: Medium
Loss of IP protection or exclusivity would weaken the company’s ability to defend OJEMDA and future products.
Exposure: OJEMDA and pipeline assets
- Reimbursement and pricing pressureImpact: MediumLikelihood: Medium
Coverage restrictions, rebates, and government cost containment can reduce realized net revenue.
Exposure: U.S. payer channel
Accounting
Judgemental itemsOJEMDA revenue is recorded net of discounts, chargebacks, rebates, specialty distributor fees, copay assistance, and returns.
Impact: Can materially change reported revenue and gross-to-net trends
The transaction price is allocated between licenses and ongoing R&D/manufacturing services, affecting timing of recognition.
Impact: Can create upfront revenue followed by deferred recognition over time
Clinical trial costs are accrued based on estimated services performed but not yet invoiced.
Impact: Affects R&D expense and liabilities when trial activity changes
A young product launch can produce uneven quarterly sales and expense patterns.
Impact: Makes period-to-period revenue and margin comparisons less stable
Similar listed companies
Publicly listed companies with a comparable business focus.
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
Benitec Biopharma Inc.
BNTC · Pharmaceutical Preparations
Crescent Biopharma, Inc
CBIO · Pharmaceutical Preparations
Ocean Biomedical, Inc.
OCEA · Pharmaceutical Preparations
Summit Therapeutics Inc.
SMMT · Pharmaceutical Preparations
Compass Therapeutics, Inc.
CMPX · Biological Products, (No Diagnostic Substances)
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapies.
Last updated: 24/09/2026